C. Robert, G. Long, B. Brady, C. Dutriaux, M. Maio et al., Mutation, New England Journal of Medicine, vol.372, issue.4, pp.320-326, 2015.
DOI : 10.1056/NEJMoa1412082
URL : https://hal.archives-ouvertes.fr/hal-00699117

J. Weber, D. Angelo, S. Minor, D. Hodi, F. Gutzmer et al., Nivolumab 328 versus chemotherapy in patients with advanced melanoma who progressed after anti- 329 CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, p.330

C. Robert, J. Schachter, G. Long, A. Arance, J. Grob et al., Pembrolizumab 332 versus Ipilimumab in Advanced Melanoma, New England Journal of Medicine, vol.333372, issue.4, pp.2521-2553, 2015.

S. Bowyer and P. Lorigan, The place of PD-1 inhibitors in melanoma management, The Lancet Oncology, vol.16, issue.8, pp.873-877, 2015.
DOI : 10.1016/S1470-2045(15)00094-7

O. Hamid, C. Robert, A. Daud, F. Hodi, W. Hwu et al., Safety and Tumor Responses with Lambrolizumab (Anti???PD-1) in Melanoma, New England Journal of Medicine, vol.369, issue.2, pp.134-178, 2013.
DOI : 10.1056/NEJMoa1305133

. Cutaneous, hepatic, endocrine, and renal side-effects of anti-PD-1 344 therapy, Eur J Cancer, vol.60, pp.190-209, 2016.

M. Mellati, K. Eaton, B. Brooks-worrell, W. Hagopian, R. Martins et al., Anti???PD-1 and Anti???PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes, Diabetes Care, vol.38, issue.9, pp.137-145, 2015.
DOI : 10.2337/dc15-0889

L. Hickmott, H. Peña, H. Turner, F. Ahmed, A. Protheroe et al., Anti- 349 PD-L1 atezolimumab-Induced Autoimmune Diabetes: a Case Report and Review of the 350

?. Activity-of-anti and . Pd-l1, Antibody in Patients with Advanced Cancer, New England Journal Medicine, vol.353366, pp.2455-65, 0354.

J. Lowe, D. Perry, A. Salama, C. Mathews, L. Moss et al., Genetic risk 355 analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to 356 combination ipilimumab and nivolumab immunotherapy, J Immunother Cancer, 2016.

M. Ansari, A. Salama, T. Chitnis, R. Smith, H. Yagita et al., The 359 programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese 360 diabetic (NOD) mice, 362 Blockade of the Programmed Death-1 (PD1) Pathway Undermines Potent Genetic 363 Protection from Type 1 Diabetes, pp.63-72, 2003.

S. Cernea and K. Herold, efficient animal model of type I diabetes Monitoring of antigen-specific CD8 T cells in patients with 369 type 1 diabetes treated with antiCD3 monoclonal antibodies, Proc Natl Acad Sci Clin Immunol, vol.102134, issue.370, pp.11823-8121, 2005.

M. Ansari, A. Salama, T. Chitnis, R. Smith, H. Yagita et al., The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice, The Journal of Experimental Medicine, vol.27, issue.1, pp.63-72, 2003.
DOI : 10.4049/jimmunol.169.11.6546

J. Martin-liberal, A. Furness, K. Joshi, K. Peggs, S. Quezada et al., Anti- 378 programmed cell death-1 therapy and insulin-dependent diabetes: a case report, Autoimmune Diabetes With Anti-PD-1 Immunotherapy, pp.55-62, 2015.

Y. Chae, L. Chiec, N. Mohindra, R. Gentzler, J. Patel et al., A case of 381 pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint 382 inhibitor-induced type 1 diabetes A case report of insulin-dependent diabetes 385 as immune-related toxicity of pembrolizumab: presentation, management and outcome. 386 Association 388 of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus 389 Triggered by Nivolumab in Patients with Non?Small Cell Lung Cancer Fulminant type 1 diabetes: a novel clinical entity 392 requiring special attention by all medical practitioners Definition, diagnosis and classification of diabetes 395 mellitus and its complications : report of a WHO consultation. Part 1, Diagnosis and 396 classification of diabetes mellitus 1999 induced by nivolumab for malignant melanoma: analysis of HLA and CTLA-4, Cancer Immunol Immunother Cancer Immunol Immunother Nat Clin Pract Endocrinol Metab, vol.662065324, issue.393, pp.25-32, 2007.

Y. Teramoto, Y. Nakamura, Y. Asami, T. Imamura, S. Takahira et al., 400 polymorphisms Case 402 of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient J 403 Dermatol 2016:n/a ? n/a Fulminant 405 type 1 diabetes mellitus with anti-programmed cell death-1 therapy Fulminant type I diabetes mellitus 408 associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma, Y. Nivolumab, an Anti-Programmed Cell Death-1, pp.383-389, 2017.

. Antibody, Induces Fulminant Type 1 Diabetes. The Tohoku Journal of Experimental 412, Medicine, vol.239, pp.155-163, 2016.

J. Brahmer, S. Tykodi, L. Chow, W. Hwu, S. Topalian et al., Safety and 417 Activity of Anti?PD-L1 Antibody in Patients with Advanced Cancer, Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes, pp.182-185, 0419.

J. Aleksova, P. Lau, G. Soldatos, G. Mcarthur, A. Imagawa et al., Glucocorticoids did not reverse type 420 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma. 421 A novel subtype of type 1 423 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related 424 antibodies, BMJ Case Reports Osaka IDDM Study Group. N Engl J Med, vol.2016342, pp.301-308, 2000.

R. East-asia-fujisawa, F. Haseda, C. Tsutsumi, Y. Hiromine, S. Noso et al., Low 429 programmed cell death-1 (PD-1) expression in peripheral CD4+ T cells in Japanese 430 patients with autoimmune type 1 diabetes, Diabetes Metab Res Rev Clin Exp Immunol, vol.27180, pp.959-64, 2011.

I. Libman, R. Laporte, and J. Tuomilehto, Geographical variation of presentation at diagnosis of type I diabetes in 437 children: the EURODIAB study European and Dibetes 439 [37] DIAMOND Project Group. Incidence and trends of childhood Type 1 diabetes 440 worldwide 1990-1999, Diabetes Diabetologia Diabet Med, vol.4423, issue.3, pp.75-80857, 2001.

H. Erlich, A. Valdes, J. Noble, J. Carlson, M. Varney et al., HLA DR-DQ 446 haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes 447 genetics consortium families ASsociation of vitiligo with tumor response 449 in patients with metastatic melanoma treated with pembrolizumab Type 2 diabetes 452 mellitus in France in 2012: results from the ObEpi survey, Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project 444 Group, pp.1516-1542, 2000.